NASDAQ:LNTH - Lantheus Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $27.00
  • Forecasted Upside: 4.41 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$25.86
▼ -0.04 (-0.15%)

This chart shows the closing price for LNTH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lantheus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LNTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LNTH

Analyst Price Target is $27.00
▲ +4.41% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Lantheus in the last 3 months. The average price target is $27.00, with a high forecast of $34.00 and a low forecast of $20.00. The average price target represents a 4.41% upside from the last price of $25.86.

This chart shows the closing price for LNTH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Lantheus. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/20/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/22/2021SVB LeerinkReiterated RatingOutperformMedium
9/26/2021SVB LeerinkReiterated RatingBuyMedium
9/19/2021SVB LeerinkReiterated RatingBuyLow
7/29/2021SVB LeerinkBoost Price TargetOutperform$31.00 ➝ $34.00Low
5/5/2021Credit Suisse GroupBoost Price TargetNeutral$17.00 ➝ $20.00Low
4/28/2021SVB LeerinkBoost Price TargetOutperform$26.00 ➝ $31.00High
2/26/2021Credit Suisse GroupBoost Price TargetNeutral$14.00 ➝ $17.00High
2/26/2021SVB LeerinkBoost Price TargetOutperform$24.00 ➝ $25.00High
2/1/2021SVB LeerinkInitiated CoverageOutperform$24.00Low
12/29/2020Credit Suisse GroupLower Price TargetNeutral$16.00 ➝ $14.00N/A
6/29/2020Jefferies Financial GroupInitiated CoverageBuy$29.00High
6/16/2020CJS SecuritiesUpgradeMarket Perform ➝ OutperformMedium
8/16/2019CJS SecuritiesUpgradeMarket Perform ➝ OutperformHigh
8/2/2018Wells Fargo & CompanyLower Price TargetOutperform$26.00 ➝ $20.00High
8/2/2018Credit Suisse GroupLower Price TargetNeutral ➝ Neutral$23.00 ➝ $21.00High
11/3/2017Jefferies Financial GroupBoost Price TargetBuy$22.00 ➝ $27.00N/A
11/3/2017Credit Suisse GroupBoost Price TargetNeutral$19.00 ➝ $23.00N/A
11/2/2017Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformN/A
10/12/2017Jefferies Financial GroupReiterated RatingBuy$22.00N/A
8/2/2017Credit Suisse GroupBoost Price TargetNeutral$14.00 ➝ $19.00N/A
8/2/2017Jefferies Financial GroupReiterated RatingBuy$18.00 ➝ $22.00High
7/17/2017Cantor FitzgeraldInitiated CoverageOverweight$22.00High
6/30/2017Jefferies Financial GroupReiterated RatingBuy$18.00Low
5/3/2017Jefferies Financial GroupBoost Price TargetBuy$15.00 ➝ $18.00Medium
4/26/2017Jefferies Financial GroupReiterated RatingBuy$15.00Medium
(Data available from 1/20/2017 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/24/2021
  • 2 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/23/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/22/2021
  • 1 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/22/2021
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
11/21/2021
  • 5 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/21/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
1/20/2022

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Lantheus logo
Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes, and assist clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment operations offers direct distribution in Canada and Puerto Rico; third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America; and EXINI business in Sweden. The company was founded in 1956 and is headquartered in North Billerica, MA.
Read More

Today's Range

Now: $25.86
Low: $25.78
High: $26.94

50 Day Range

MA: $27.90
Low: $25.86
High: $30.44

52 Week Range

Now: $25.86
Low: $15.27
High: $31.60

Volume

265,465 shs

Average Volume

320,513 shs

Market Capitalization

$1.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Lantheus?

The following Wall Street research analysts have issued reports on Lantheus in the last year: Credit Suisse Group AG, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for LNTH.

What is the current price target for Lantheus?

2 Wall Street analysts have set twelve-month price targets for Lantheus in the last year. Their average twelve-month price target is $27.00, suggesting a possible upside of 4.4%. SVB Leerink LLC has the highest price target set, predicting LNTH will reach $34.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $20.00 for Lantheus in the next year.
View the latest price targets for LNTH.

What is the current consensus analyst rating for Lantheus?

Lantheus currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LNTH will outperform the market and that investors should add to their positions of Lantheus.
View the latest ratings for LNTH.

How do I contact Lantheus' investor relations team?

Lantheus' physical mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider's listed phone number is (978) 671-8001 and its investor relations email address is [email protected] The official website for Lantheus is www.lantheus.com.